Methylnaltrexone

DRUG19 trials

Sponsors

Bausch Health Americas, Inc., Region Örebro County, Shiraz University of Medical Sciences, Drexel University, University Medicine Greifswald

Conditions

ConstipationCoronary Artery DiseaseEsophageal DysfunctionGastroparesisHead and Neck Squamous Cell CarcinomaHealthy Adult SubjectsHealthy AdultsIntestinal Obstruction

Phase 1

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

CompletedNCT01366365

Bausch Health Americas, Inc.Healthy Adults

Start: 2006-10-31End: 2006-11-30Updated: 2019-11-27

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

CompletedNCT01366378

Bausch Health Americas, Inc.Healthy Adult Subjects

Start: 2007-01-31End: 2007-02-28Updated: 2019-11-27

Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.

CompletedNCT01596764

University Medicine GreifswaldIntestinal Obstruction

Start: 2011-05-31End: 2012-01-31Updated: 2012-05-11

Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients

CompletedNCT01889290

University of ZurichOpioid Use, Unspecified With Other Opioid-induced Disorder

Start: 2014-02-28End: 2016-06-30Updated: 2016-10-26

Phase 2

Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients

TerminatedNCT01117376

Shiraz University of Medical SciencesGastroparesis

Start: 2010-05-31End: 2011-08-31Target: 42Updated: 2011-03-31

Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention

CompletedNCT03852524

Ohio State UniversityPostoperative Ileus

Start: 2019-02-21End: 2021-05-12Updated: 2021-10-27

Phase 3

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

CompletedNCT00401375

Bausch Health Americas, Inc.Post-Operative Ileus (POI)

Start: 2006-10-31End: 2008-02-29Updated: 2019-09-04

Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

CompletedNCT00936884

Bausch Health Americas, Inc.Constipation

Start: 2009-07-31End: 2013-11-30Updated: 2020-01-02

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

CompletedNCT01186770

Bausch Health Americas, Inc.Opioid-Induced Constipation

Start: 2010-09-01End: 2011-09-08Updated: 2019-09-06

Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates

WithdrawnNCT01360372

Drexel UniversityTube Feeding

Start: 2010-10-31End: 2012-05-31Updated: 2015-03-17

Phase 4

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

CompletedNCT00672477

Bausch Health Americas, Inc.Opioid-Induced Constipation

Start: 2008-06-30End: 2013-02-28Updated: 2018-03-08

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

WithdrawnNCT00858754

Bausch Health Americas, Inc.Opioid-Induced Constipation

Start: 2009-03-31End: 2009-08-31Updated: 2019-11-29

Opioids and Esophageal Function

CompletedNCT01012960

Region Örebro CountyEsophageal Dysfunction, Pharyngeal Dysfunction

Start: 2009-11-30End: 2010-01-31Updated: 2011-12-09

Methylnaltrexone Use for Opioid-induced Postoperative Constipation

CompletedNCT01773096

Shriners Hospitals for ChildrenConstipation

Start: 2013-05-31End: 2015-05-31Target: 60Updated: 2015-05-19

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

CompletedNCT02403830

University of FloridaCoronary Artery Disease

Start: 2015-08-31End: 2016-05-31Updated: 2017-05-30

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

TerminatedNCT02977286

Tufts Medical CenterConstipation

Start: 2017-01-01End: 2019-10-09Updated: 2023-02-16

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A Window of Opportunity Pilot Study.

RecruitingNCT06162377

M.D. Anderson Cancer CenterHead and Neck Squamous Cell Carcinoma

Start: 2024-01-10End: 2026-12-31Target: 25Updated: 2025-12-17

Unknown Phase

Compassionate Use Study of Methylnaltrexone

CompletedNCT01368562

Bausch Health Americas, Inc.Opioid-induced Constipation

Start: 2003-01-24End: 2008-06-02Updated: 2019-09-04

Methylnaltrexone for Opioid Induced Constipation

TerminatedNCT01955213

Amsterdam UMC, location VUmcConstipation

Start: 2012-07-31End: 2017-09-30Updated: 2019-08-05

Related Papers

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness.

2023-10-201 citations

Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials.

2023-02-101 citations

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation.

2023-01-29

S165 Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

The American Journal of Gastroenterology2022-10-01

Design and feasibility of a double-blind, randomized trial of peri-operative methylnaltrexone for postoperative ileus prevention after adult spinal arthrodesis.

2021-11-171 citations

S187 A Pooled Analysis of the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Severe Medical Illness: The Impact of Baseline Opioid Equivalent Dose

The American Journal of Gastroenterology2021-10-01

Rescue-free laxation response with methylnaltrexone treatment in cancer patients with opioid-induced constipation: The impact of baseline ECOG status.

Journal of Clinical Oncology2021-05-20

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.

2021-03-314 citations

Error in Figure

JAMA Internal Medicine2021-03-29

S0493 Subcutaneous Methylnaltrexone in Cancer and Non-Cancer Patients for Rapid Relief of Opioid-Induced Constipation

The American Journal of Gastroenterology2020-10-01

Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.

2019-07-3122 citations

Optimal treatment of opioid induced constipation in daily clinical practice – an observational study

BMC Palliative Care2019-03-2922 citations

Efficacy variables in patients with cancer versus patients without cancer treated with methylnaltrexone or placebo: An analysis of two placebo-controlled studies.

Journal of Clinical Oncology2018-11-284 citations

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.

2016-08-2973 citations

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone

BMC Palliative Care2014-08-2016 citations